![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NCK2 |
Gene summary for NCK2 |
![]() |
Gene information | Species | Human | Gene symbol | NCK2 | Gene ID | 8440 |
Gene name | NCK adaptor protein 2 | |
Gene Alias | GRB4 | |
Cytomap | 2q12.2 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A0A0S2Z4M6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8440 | NCK2 | CCI_1 | Human | Cervix | CC | 1.34e-04 | 6.41e-01 | 0.528 |
8440 | NCK2 | CCI_3 | Human | Cervix | CC | 5.98e-08 | 8.91e-01 | 0.516 |
8440 | NCK2 | C04 | Human | Oral cavity | OSCC | 6.53e-07 | 5.94e-01 | 0.2633 |
8440 | NCK2 | C21 | Human | Oral cavity | OSCC | 1.33e-05 | 4.28e-01 | 0.2678 |
8440 | NCK2 | C30 | Human | Oral cavity | OSCC | 1.48e-24 | 1.15e+00 | 0.3055 |
8440 | NCK2 | C38 | Human | Oral cavity | OSCC | 2.40e-05 | 8.24e-01 | 0.172 |
8440 | NCK2 | C43 | Human | Oral cavity | OSCC | 9.54e-10 | 2.48e-01 | 0.1704 |
8440 | NCK2 | C46 | Human | Oral cavity | OSCC | 1.93e-09 | 3.27e-01 | 0.1673 |
8440 | NCK2 | C51 | Human | Oral cavity | OSCC | 9.64e-07 | 6.24e-01 | 0.2674 |
8440 | NCK2 | C57 | Human | Oral cavity | OSCC | 1.41e-05 | 3.71e-01 | 0.1679 |
8440 | NCK2 | C08 | Human | Oral cavity | OSCC | 8.04e-11 | 2.14e-01 | 0.1919 |
8440 | NCK2 | LN38 | Human | Oral cavity | OSCC | 2.21e-02 | 7.23e-01 | 0.168 |
8440 | NCK2 | EOLP-1 | Human | Oral cavity | EOLP | 1.55e-02 | 1.59e-01 | -0.0202 |
8440 | NCK2 | NEOLP-3 | Human | Oral cavity | NEOLP | 6.99e-04 | 2.25e-01 | -0.0191 |
8440 | NCK2 | SYSMH1 | Human | Oral cavity | OSCC | 1.71e-12 | 3.15e-01 | 0.1127 |
8440 | NCK2 | SYSMH2 | Human | Oral cavity | OSCC | 2.11e-14 | 3.97e-01 | 0.2326 |
8440 | NCK2 | SYSMH3 | Human | Oral cavity | OSCC | 4.80e-17 | 4.65e-01 | 0.2442 |
8440 | NCK2 | SYSMH5 | Human | Oral cavity | OSCC | 1.58e-04 | 1.17e-01 | 0.0647 |
8440 | NCK2 | SYSMH6 | Human | Oral cavity | OSCC | 2.39e-07 | 2.47e-01 | 0.1275 |
8440 | NCK2 | P1_S1_AK | Human | Skin | AK | 8.08e-08 | 3.48e-01 | -0.3399 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00706656 | Cervix | CC | positive regulation of leukocyte proliferation | 30/2311 | 150/18723 | 4.93e-03 | 2.95e-02 | 30 |
GO:00331353 | Cervix | CC | regulation of peptidyl-serine phosphorylation | 29/2311 | 144/18723 | 5.10e-03 | 3.01e-02 | 29 |
GO:00421024 | Cervix | CC | positive regulation of T cell proliferation | 22/2311 | 101/18723 | 5.30e-03 | 3.10e-02 | 22 |
GO:00506713 | Cervix | CC | positive regulation of lymphocyte proliferation | 27/2311 | 137/18723 | 8.99e-03 | 4.57e-02 | 27 |
GO:00329463 | Cervix | CC | positive regulation of mononuclear cell proliferation | 27/2311 | 138/18723 | 9.89e-03 | 4.85e-02 | 27 |
GO:200123320 | Oral cavity | OSCC | regulation of apoptotic signaling pathway | 242/7305 | 356/18723 | 6.66e-29 | 3.24e-26 | 242 |
GO:009719320 | Oral cavity | OSCC | intrinsic apoptotic signaling pathway | 202/7305 | 288/18723 | 4.64e-27 | 1.73e-24 | 202 |
GO:003497620 | Oral cavity | OSCC | response to endoplasmic reticulum stress | 178/7305 | 256/18723 | 2.59e-23 | 6.06e-21 | 178 |
GO:000641318 | Oral cavity | OSCC | translational initiation | 96/7305 | 118/18723 | 4.02e-21 | 7.06e-19 | 96 |
GO:200124220 | Oral cavity | OSCC | regulation of intrinsic apoptotic signaling pathway | 123/7305 | 164/18723 | 5.71e-21 | 9.77e-19 | 123 |
GO:003596620 | Oral cavity | OSCC | response to topologically incorrect protein | 117/7305 | 159/18723 | 6.93e-19 | 8.60e-17 | 117 |
GO:004325420 | Oral cavity | OSCC | regulation of protein-containing complex assembly | 255/7305 | 428/18723 | 2.94e-18 | 3.15e-16 | 255 |
GO:000641720 | Oral cavity | OSCC | regulation of translation | 274/7305 | 468/18723 | 4.39e-18 | 4.63e-16 | 274 |
GO:000698620 | Oral cavity | OSCC | response to unfolded protein | 103/7305 | 137/18723 | 6.47e-18 | 6.50e-16 | 103 |
GO:004572719 | Oral cavity | OSCC | positive regulation of translation | 101/7305 | 136/18723 | 5.85e-17 | 4.94e-15 | 101 |
GO:003425019 | Oral cavity | OSCC | positive regulation of cellular amide metabolic process | 115/7305 | 162/18723 | 1.28e-16 | 1.05e-14 | 115 |
GO:003133420 | Oral cavity | OSCC | positive regulation of protein-containing complex assembly | 153/7305 | 237/18723 | 1.18e-15 | 8.33e-14 | 153 |
GO:200123510 | Oral cavity | OSCC | positive regulation of apoptotic signaling pathway | 92/7305 | 126/18723 | 8.45e-15 | 5.19e-13 | 92 |
GO:00064469 | Oral cavity | OSCC | regulation of translational initiation | 64/7305 | 79/18723 | 2.32e-14 | 1.30e-12 | 64 |
GO:001056320 | Oral cavity | OSCC | negative regulation of phosphorus metabolic process | 246/7305 | 442/18723 | 6.12e-13 | 2.89e-11 | 246 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0401210 | Cervix | CC | ErbB signaling pathway | 28/1267 | 85/8465 | 2.40e-05 | 1.82e-04 | 1.08e-04 | 28 |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa046604 | Cervix | CC | T cell receptor signaling pathway | 25/1267 | 104/8465 | 9.52e-03 | 2.94e-02 | 1.74e-02 | 25 |
hsa05130110 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0401213 | Cervix | CC | ErbB signaling pathway | 28/1267 | 85/8465 | 2.40e-05 | 1.82e-04 | 1.08e-04 | 28 |
hsa0436012 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa0466011 | Cervix | CC | T cell receptor signaling pathway | 25/1267 | 104/8465 | 9.52e-03 | 2.94e-02 | 1.74e-02 | 25 |
hsa0513030 | Oral cavity | OSCC | Pathogenic Escherichia coli infection | 129/3704 | 197/8465 | 4.32e-10 | 5.17e-09 | 2.63e-09 | 129 |
hsa046606 | Oral cavity | OSCC | T cell receptor signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa0401216 | Oral cavity | OSCC | ErbB signaling pathway | 55/3704 | 85/8465 | 7.46e-05 | 2.81e-04 | 1.43e-04 | 55 |
hsa0436014 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa05130114 | Oral cavity | OSCC | Pathogenic Escherichia coli infection | 129/3704 | 197/8465 | 4.32e-10 | 5.17e-09 | 2.63e-09 | 129 |
hsa0466012 | Oral cavity | OSCC | T cell receptor signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa0401217 | Oral cavity | OSCC | ErbB signaling pathway | 55/3704 | 85/8465 | 7.46e-05 | 2.81e-04 | 1.43e-04 | 55 |
hsa0436015 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa0513045 | Oral cavity | EOLP | Pathogenic Escherichia coli infection | 54/1218 | 197/8465 | 1.10e-06 | 9.96e-06 | 5.87e-06 | 54 |
hsa0466021 | Oral cavity | EOLP | T cell receptor signaling pathway | 34/1218 | 104/8465 | 1.63e-06 | 1.39e-05 | 8.18e-06 | 34 |
hsa0401223 | Oral cavity | EOLP | ErbB signaling pathway | 27/1218 | 85/8465 | 3.39e-05 | 1.69e-04 | 9.94e-05 | 27 |
hsa0436023 | Oral cavity | EOLP | Axon guidance | 38/1218 | 182/8465 | 1.02e-02 | 2.80e-02 | 1.65e-02 | 38 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCK2 | SNV | Missense_Mutation | novel | c.122N>G | p.Val41Gly | p.V41G | O43639 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A1G6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
NCK2 | SNV | Missense_Mutation | novel | c.568N>G | p.Asn190Asp | p.N190D | O43639 | protein_coding | tolerated(0.25) | benign(0.062) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
NCK2 | SNV | Missense_Mutation | novel | c.547C>T | p.Arg183Cys | p.R183C | O43639 | protein_coding | deleterious(0.04) | possibly_damaging(0.513) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NCK2 | SNV | Missense_Mutation | novel | c.60N>T | p.Glu20Asp | p.E20D | O43639 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
NCK2 | SNV | Missense_Mutation | rs370241867 | c.872N>T | p.Thr291Met | p.T291M | O43639 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NCK2 | SNV | Missense_Mutation | rs754330998 | c.548N>A | p.Arg183His | p.R183H | O43639 | protein_coding | tolerated(0.33) | benign(0.255) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
NCK2 | SNV | Missense_Mutation | c.1028N>A | p.Cys343Tyr | p.C343Y | O43639 | protein_coding | tolerated(0.06) | possibly_damaging(0.9) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
NCK2 | SNV | Missense_Mutation | rs766993432 | c.592C>T | p.His198Tyr | p.H198Y | O43639 | protein_coding | deleterious(0.02) | benign(0.209) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NCK2 | SNV | Missense_Mutation | novel | c.826T>C | p.Ser276Pro | p.S276P | O43639 | protein_coding | tolerated(0.28) | benign(0) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NCK2 | SNV | Missense_Mutation | rs780151498 | c.836G>A | p.Arg279His | p.R279H | O43639 | protein_coding | tolerated(0.28) | benign(0.003) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |